REPATH LAUNCH
15 September 2026
Global
The launch of REPATH — Genspect's Re-psychopathologisation Campaign — marks a formal push to restore psychiatric assessment and differential diagnosis to the clinical response to gender distress. Stella O'Malley and Mia Hughes set out the argument: that automatic affirmation has displaced rigorous clinical enquiry, with consequences the Cass Review documented at length. For the UK, where NHS England has already moved away from unsupervised affirmation pathways, REPATH frames the next necessary step: embedding thorough psychiatric and psychological care as the professional standard.
REPATH — the Re-psychopathologisation Campaign launched by Genspect — represents one of the most substantive clinical and policy proposals to emerge from the evidence-critical space in gender medicine. Stella O'Malley, psychotherapist and co-founder of Genspect, joins Mia Hughes to mark the campaign's public launch and to explain precisely what re-psychopathologisation means and, equally importantly, what it does not mean. The campaign's central argument is that transgender ideation — persistent gender distress or the conviction that one belongs to the opposite sex — should be understood within a psychiatric framework. This is not a call to pathologise gender non-conformity or same-sex attraction. Rather, it is a demand that clinicians conduct thorough differential diagnosis before any social, hormonal or surgical intervention, taking time to explore whether co-occurring conditions such as autism, trauma, depression, OCD or dissociative disorders might be driving or shaping the presenting distress. The relevance to the United Kingdom is immediate. The Cass Review, published in April 2024, reached closely parallel conclusions through four years of independent evidence synthesis. Hilary Cass found that the affirmation model as practised at the Gender Identity Development Service had systematically bypassed the psychiatric and psychological assessment that would be standard for any comparable clinical presentation. She called for a fundamentally different approach — exploratory, assessment-led, cautious about medical pathways for children and attentive to the full picture of a young person's mental health. NHS England has since closed the GIDS model, restricted puberty blocker prescribing outside research settings and is building new regional services around holistic assessment. REPATH presses that logic further, arguing that the problem is not merely one of service design but of diagnostic classification. When gender distress is progressively removed from psychiatric classification systems — as has occurred since the 1990s and most recently through ICD-11 — clinicians lose the institutional frameworks that justify careful, time-consuming assessment before proceeding. The incentive structure shifts toward rapid affirmation rather than thorough enquiry. For practitioners in the UK navigating a post-Cass environment, this raises live questions that professional bodies including the British Psychological Society and the Royal College of Psychiatrists have not yet fully resolved. Whether formal psychiatric assessment should be reinstated as a prerequisite for gender-related care — not an optional add-on — will shape what the new NHS regional hubs actually deliver in practice. O'Malley's clinical background working with gender-distressed young people and families, and Hughes's research focus on the evidence base, make them well placed to articulate the campaign's aims. REPATH gives those arguments an organised framework with an explicit goal: to influence diagnostic classifications, clinical standards and the policy decisions that determine how gender distress is met in consulting rooms across the UK and internationally.
